Table 2.
Correlation between PD-L1 expression and clinicopathological parameters.
| PD-L1(-)% | PD-L1(+)% | P value | |
| Age (yrs) | 0.051 | ||
| ≤50 | 333 (57.3) | 248 (42.7) | |
| >50 | 433 (62.4) | 260 (37.6) | |
| tumor size (cm) | 0.466 | ||
| ≤2 | 246 (50.8) | 238 (49.2) | |
| >2 | 322 (53.0) | 285 (47) | |
| Histologic grade | 0.779 | ||
| I | 424 (74.1) | 148 (25.9) | |
| II | 1110 (73.4) | 402 (26.6) | |
| III | 977 (72.6) | 368 (27.4) | |
| Tumor stage | 0.015 | ||
| PT1 | 662 (78.3) | 184 (21.7) | |
| PT2 | 875 (78.1) | 246 (21.9) | |
| PT3 | 84 (71.8) | 33 (28.2) | |
| PT4 | 70 (66.0) | 36 (34.0) | |
| Lymph node metastasis | 0.007 | ||
| (–) | 1007 (72.1) | 390 (27.9) | |
| (+) | 802 (67.2) | 391 (32.8) | |
| ER status | .000 | ||
| (–) | 897 (73.2) | 328 (26.8) | |
| (+) | 1741 (80.2) | 429 (19.8) | |
| PR status | .167 | ||
| (–) | 950 (75.5) | 309 (24.5) | |
| (+) | 972 (73.1) | 358 (26.9) | |
| HER2 status | 0.030 | ||
| (–) | 2122 (73.7) | 758 (26.3) | |
| (+) | 508 (69.7) | 221 (30.3) | |
| Molecular subtype | 0.043 | ||
| Luminal A | 762 (75.3) | 250 (24.7) | |
| Luminal B | 570 (70.3) | 241 (29.7) | |
| Her2 rich | 209 (77.4) | 61 (22.6) | |
| TNBC | 346 (73.2) | 127 (26.8) | |
| Ki-67 expression | 0.000 | ||
| Low | 1283 (78.5) | 352 (21.5) | |
| High | 951 (69.0) | 428 (31.0) |
ER = estrogen receptor, PR = progesterone receptor, T = tumor, P < .05: statistically significant.